Biologic and small-molecule medications in the management of pyoderma gangrenosum

References

• Miller J, Yentzer BA, Clark A. Pyoderma gangrenosum: a review and update on new therapies. J Am Acad Dermatol. 2010;62:646–654.
   PubMed Web of Science ®Google Scholar
• Marzano AV, Fanoni D, Antiga E. Expression of cytokines, chemokines and other effector molecules in two prototypic autoinflammatory skin diseases, pyoderma gangrenosum and Sweet’s syndrome. Clin Exp Immunol. 2014;178:48–56.
   PubMed Web of Science ®Google Scholar
• Alves de Medeiros AK, Speeckaert R, Desmet E, et al. JAK3 as an emerging target for topical treatment of inflammatory skin diseases. PLoS One. 2016;11:e0164080.
   PubMed Web of Science ®Google Scholar
• Guenova E, Teske A, Fehrenbacher B, et al. Interleukin 23 expression in pyoderma gangrenosum and targeted therapy with ustekinumab. Arch Dermatol. 2011;147:1203–1205.
   PubMedGoogle Scholar
• Okuma K, Mitsuishi K, Hasegawa T, et al. A case report of steroid and immunosuppressant-resistant pyoderma gangrenosum successfully treated by granulocytapheresis. Therapher Dial. 2007;11:387–390.
   PubMed Web of Science ®Google Scholar
• Montoto S, Bosch F, Estrach T, et al. Pyoderma gangrenosum triggered by alpha2b-interferon in a patient with chronic granulocytic leukemia. Leuk. Lymphoma. 1998;30:199–202.
   Web of Science ®Google Scholar
• Kawakami T, Yamazaki M, Soma Y. Reduction of interleukin-6, interleukin-8, and anti-phosphatidylserine-prothrombin complex antibody by granulocyte and monocyte adsorption apheresis in a patient with pyoderma gangrenosum and ulcerative colitis. Am J Gastroenterol. 2009;104:2363–2364.
   PubMed Web of Science ®Google Scholar
• Kozono K, Nakahara T, Kikuchi S, et al. Pyoderma gangrenosum with increased levels of serum cytokines. J Dermatol. 2015;42:1186–1188.
   PubMed Web of Science ®Google Scholar
• Braswell SF, Kostopoulos TC, Ortega-Loayza AG. Pathophysiology of pyoderma gangrenosum (PG): an updated review. J Am Acad Dermatol. 2015;73:691–698.
   PubMed Web of Science ®Google Scholar
• Brennan FM, Chantry D, Jackson A, et al. Inhibitory effect of TNF alpha antibodies on synovial cell interleukin-1 production in rheumatoid arthritis. Lancet. 1989;2:244–247.
   PubMed Web of Science ®Google Scholar
• Elliott MJ, Maini RN, Feldmann M, et al. Treatment of rheumatoid arthritis with chimeric monoclonal antibodies to tumor necrosis factor alpha. Arthritis Rheum. 1993;36:1681–1690.
   PubMed Web of Science ®Google Scholar
• Tak PP, Taylor PC, Breedveld FC, et al. Decrease in cellularity and expression of adhesion molecules by anti-tumor necrosis factor alpha monoclonal antibody treatment in patients with rheumatoid arthritis. Arthritis Rheum. 1996;39:1077–1081.
   PubMed Web of Science ®Google Scholar
• Hubbard VG, Friedmann AC, Goldsmith P. Systemic pyoderma gangrenosum responding to infliximab and adalimumab. Br J Dermatol. 2005;152:1059–1061.
   PubMed Web of Science ®Google Scholar
• Agarwal A, Andrews JM. Systematic review: IBD-associated pyoderma gangrenosum in the biologic era, the response to therapy. Aliment Pharmacol Ther. 2013;38:563–572.
   PubMed Web of Science ®Google Scholar
• Klotz U, Teml A, Schwab M. Clinical pharmacokinetics and use of infliximab. Clin Pharmacokinet. 2007;46:645–660.
   PubMed Web of Science ®Google Scholar
• Knight DM, Trinh H, Le J, et al. Construction and initial characterization of a mouse-human chimeric anti-TNF antibody. Mol Immunol. 1993;30:1443–1453.
   PubMed Web of Science ®Google Scholar
• Vena GA, Cassano N. Drug focus: adalimumab in the treatment of moderate to severe psoriasis. Biologics. 2007;1:93–103.
   PubMedGoogle Scholar
• Janssen Biotech Inc. Remicade (infliximab) prescribing information. US FDA Safety Information. 2015.
   Google Scholar
• Brooklyn TN, Dunnill MG, Shetty A, et al. Infliximab for the treatment of pyoderma gangrenosum: a randomised, double blind, placebo controlled trial. Gut. 2006;55:505–509.
   PubMed Web of Science ®Google Scholar
• Traczewski P, Rudnicka L. Adalimumab in dermatology. Br J Clin Pharmacol. 2008;66:618–625.
   PubMed Web of Science ®Google Scholar
• AbbVie Inc. Humira (adalimumab) prescribing information. US FDA Safety Information. 2016.
   Google Scholar
• Hadziselimovic F. Adalimumab induces and maintains remission in severe, resistant paediatric Crohn disease. J Pediatr Gastroenterol Nutr. 2008;46:208–211.
   PubMed Web of Science ®Google Scholar
• Jacob SE, Weisman RS, Kerdel FA. Pyoderma gangrenosum-rebel without a cure? Int J Dermatol. 2008;47:192–194.
   PubMed Web of Science ®Google Scholar
• Campanati A, Brisigotti V, Ganzetti G, et al. Finally, recurrent pyoderma gangrenosum treated with Adalimumab: case report and review of the literature. J Eur Acad Dermatol Venereol. 2015;29:1245–1247.
   PubMed Web of Science ®Google Scholar
• Heffernan MP, Anadkat MJ, Smith DI. Adalimumab treatment for pyoderma gangrenosum. Arch Dermatol. 2007;143:306–308.
   PubMedGoogle Scholar
• Carinanos I, Acosta MB, Domenech E. Adalimumab for pyoderma gangrenosum associated with inflammatory bowel disease. Inflamm Bowel Dis. 2011;17:E153–E154.
   PubMed Web of Science ®Google Scholar
• Lee H, Park SH, Kim SK, et al. Pyogenic arthritis, pyoderma gangrenosum, and acne syndrome (PAPA syndrome) with E250K mutation in CD2BP1 gene treated with the tumor necrosis factor inhibitor adalimumab. Clin Exp Rheumatol. 2012;30:452.
   PubMed Web of Science ®Google Scholar
• Hinterberger L, Muller CS, Vogt T, et al. Adalimumab: a treatment option for pyoderma gangrenosum after failure of systemic standard therapies. Dermatol Ther. 2012;2:6.
   PubMedGoogle Scholar
• Saraceno R, Babino G, Chiricozzi A, et al. PsAPASH: a new syndrome associated with hidradenitis suppurativa with response to tumor necrosis factor inhibition. J Am Acad Dermatol. 2015;72:e42–e44.
   PubMed Web of Science ®Google Scholar
• Sharon V, Burrall B, Patel F, et al. Multimodal therapy of idiopathic pyoderma gangrenosum. Dermatol Online J. 2014;20:13030/qt5s5397rd.
   Google Scholar
• Murphy B, Morrison G, Podmore P. Successful use of adalimumab to treat pyoderma gangrenosum, acne and suppurative hidradenitis (PASH syndrome) following colectomy in ulcerative colitis. Int J Colorectal Dis. 2015;30:1139–1140.
   PubMed Web of Science ®Google Scholar
• Zold E, Nagy A, Devenyi K, et al. Successful use of adalimumab for treating fistulizing Crohn’s disease with pyoderma gangrenosum: two birds with one stone. World J Gastroenterol. 2009;15:2293–2295.
   PubMed Web of Science ®Google Scholar
• Pomerantz RG, Husni ME, Mody E, et al. Adalimumab for treatment of pyoderma gangrenosum. Br J Dermatol. 2007;157:1274–1275.
   PubMed Web of Science ®Google Scholar
• Fonder MA, Cummins DL, Ehst BD, et al. Adalimumab therapy for recalcitrant pyoderma gangrenosum. J Burns Wounds. 2006;5:e8.
   PubMedGoogle Scholar
• Reddick CL, Singh MN, Chalmers RJ. Successful treatment of superficial pyoderma gangrenosum associated with hidradenitis suppurativa with adalimumab. Dermatol Online J. 2010;16:15.
   PubMedGoogle Scholar
• Alkhouri N, Hupertz V, Mahajan L. Adalimumab treatment for peristomal pyoderma gangrenosum associated with Crohn’s disease. Inflamm Bowel Dis. 2009;15:803–806.
   PubMed Web of Science ®Google Scholar
• Lipka S, Katz S, Ginzburg L. Massive pyoderma gangrenosum in a 77 year old female with Crohn’s disease responsive to adalimumab. J Crohns Colitis. 2013;7:427–428.
   PubMed Web of Science ®Google Scholar
• Sagami S, Ueno Y, Tanaka S, et al. Successful use of adalimumab for treating pyoderma gangrenosum with ulcerative colitis under corticosteroid-tapering conditions. Intern Med. 2015;54:2167–2172.
   PubMed Web of Science ®Google Scholar
• Cerdan-Santacruz C, Caparros-Sanz MR, Lancharro-Bermudez M, et al. Peri-ileostomy pyoderma gangrenosum. Case report. Rev Esp Enferm Dig. 2014;106:285–288.
   PubMed Web of Science ®Google Scholar
• Kleinpenning MM, Langewouters AM, Van De Kerkhof PC, et al. Severe pyoderma gangrenosum unresponsive to etanercept and adalimumab. J Dermatolog Treat. 2011;22:261–265.
   PubMed Web of Science ®Google Scholar
• Fakhar F, Memon S, Deitz D, et al. Refractory postsurgical pyoderma gangrenosum in a patient with Beckwith Wiedemann syndrome: response to multimodal therapy. BMJ Case Rep. 2013;2013:bcr2013201084.
   PubMedGoogle Scholar
• Arguelles-Arias F, Castro-Laria L, Lobaton T, et al. Characteristics and treatment of pyoderma gangrenosum in inflammatory bowel disease. Dig Dis Sci. 2013;58:2949–2954.
   PubMed Web of Science ®Google Scholar
• Arivarasan K, Bhardwaj V, Sud S, et al. Biologics for the treatment of pyoderma gangrenosum in ulcerative colitis. Intest Res. 2016;14:365–368.
   PubMed Web of Science ®Google Scholar
• Staub J, Pfannschmidt N, Strohal R, et al. Successful treatment of PASH syndrome with infliximab, cyclosporine and dapsone. J Eur Acad Dermatol Venereol. 2015;29:2243–2247.
   PubMed Web of Science ®Google Scholar
• Vahlquist A, Hakansson LD, Ronnblom L, et al. Recurrent pyoderma gangrenosum and cystic acne associated with leucocyte adhesion deficiency due to novel mutations in ITGB2: successful treatment with infliximab and adalimumab. Acta Derm Venereol. 2015;95:349–351.
   PubMed Web of Science ®Google Scholar
• Barreiro-de-Acosta M, Lorenzo A, Domínguez-Muñoz JE. Efficacy of adalimumab for the treatment of extraintestinal manifestations of Crohn’s disease. Rev Esp Enferm Dig. 2012;104:468–472.
   PubMed Web of Science ®Google Scholar
• Galimberti RL, Vacas AS, Bollea Garlatti ML, et al. The role of interleukin-1β in pyoderma gangrenosum. JAAD Case Rep. 2016;2:366–368.
   PubMedGoogle Scholar
• Sand FL, Thomsen SF. Off-label use of TNF-alpha inhibitors in a dermatological university department: retrospective evaluation of 118 patients. Dermatol Ther. 2015;28:158–165.
   PubMed Web of Science ®Google Scholar
• Stichenwirth M, Riedl E, Pehamberger H, et al. Pyoderma gangrenosum in a patient with seronegative rheumatoid arthritis during therapy with adalimumab: toxic effects of adalimumab or failure of adalimumab to prevent the onset of this phenomenon? Arch Dermatol. 2008;144:817–818.
   PubMedGoogle Scholar
• Kikuchi N, Hiraiwa T, Ohashi T, et al. Pyoderma gangrenosum possibly triggered by adalimumab. Eur J Dermatol. 2012;22:804–805.
   PubMed Web of Science ®Google Scholar
• Lee JH, Chang IK, Lee HE, et al. Treatment of recalcitrant pyoderma gangrenosum with ulcerative colitis by adalimumab injection. Ann Dermatol. 2017;29:260–262.
   PubMed Web of Science ®Google Scholar
• Bardazzi F, Magnano M, Tengattini V, et al. Pyoderma gangrenosum in the genital area: successful treatment using adalimumab. Eur J Dermatol. 2018;28:263–264.
   PubMed Web of Science ®Google Scholar
• De Wet J, Jordaan HF, Kannenberg SM, et al. Pyoderma gangrenosum, acne, and suppurative hidradenitis syndrome in end-stage renal disease successfully treated with adalimumab. Dermatol Online J. 2017;23(12):1–6.
   Google Scholar
• Vekic DA, Woods J, Lin P, et al. SAPHO syndrome associated with hidradenitis suppurativa and pyoderma gangrenosum successfully treated with adalimumab and methotrexate: a case report and review of the literature. Int J Dermatol. 2018;57:10–18.
   PubMed Web of Science ®Google Scholar
• Mitoma H, Horiuchi T, Tsukamoto H, et al. Molecular mechanisms of action of anti-TNF-alpha agents – comparison among therapeutic TNF-alpha antagonists. Cytokine. 2018;101:56–63.
   PubMed Web of Science ®Google Scholar
• Mohler KM, Torrance DS, Smith CA, et al. Soluble tumor necrosis factor (TNF) receptors are effective therapeutic agents in lethal endotoxemia and function simultaneously as both TNF carriers and TNF antagonists. J Immunol. 1993;151:1548–1561.
   PubMed Web of Science ®Google Scholar
• Immunex Corporation. Enbrel (etanercept) prescribing information. US FDA Safety Information. 2015.
   Google Scholar
• Disla E, Quayum B, Cuppari GG, et al. Successful use of etanercept in a patient with pyoderma gangrenosum complicating rheumatoid arthritis. J Clin Rheumatol. 2004;10:50–52.
   PubMed Web of Science ®Google Scholar
• Rogge FJ, Pacifico M, Kang N. Treatment of pyoderma gangrenosum with the anti-TNFalpha drug – rtanercept. J Plast Reconstr Aesthet Surg. 2008;61:431–433.
   PubMed Web of Science ®Google Scholar
• Tofteland ND, Shaver TS. Clinical efficacy of etanercept for treatment of PAPA syndrome. J Clin Rheumatol. 2010;16:244–245.
   PubMed Web of Science ®Google Scholar
• Kim FS, Pandya AG. The use of etanercept in the treatment of peristomal pyoderma gangrenosum. Clin Exp Dermatol. 2012;37:442–443.
   PubMed Web of Science ®Google Scholar
• McGowan JWt, Johnson CA, Lynn A. Treatment of pyoderma gangrenosum with etanercept. J Drugs Dermatol. 2004;3:441–444.
   PubMedGoogle Scholar
• Goldenberg G, Jorizzo JL. Use of etanercept in treatment of pyoderma gangrenosum in a patient with autoimmune hepatitis. J Dermatolog Treat. 2005;16:347–349.
   PubMed Web of Science ®Google Scholar
• Charles CA, Leon A, Banta MR, et al. Etanercept for the treatment of refractory pyoderma gangrenosum: a brief series. Int J Dermatol. 2007;46:1095–1099.
   PubMed Web of Science ®Google Scholar
• Pastor N, Betlloch I, Pascual JC, et al. Pyoderma gangrenosum treated with anti-TNF alpha therapy (etanercept). Clin Exp Dermatol. 2006;31:152–153.
   PubMed Web of Science ®Google Scholar
• Roy DB, Conte ET, Cohen DJ. The treatment of pyoderma gangrenosum using etanercept. J Am Acad Dermatol. 2006;54:S128–S134.
   PubMed Web of Science ®Google Scholar
• Bruzzese V. Pyoderma gangrenosum, acne conglobata, suppurative hidradenitis, and axial spondyloarthritis: efficacy of anti-tumor necrosis factor alpha therapy. J Clin Rheumatol. 2012;18:413–415.
   PubMed Web of Science ®Google Scholar
• Rallis E, Koumantaki-Mathioudaki E, Tsiatoura A, et al. Pyoderma gangrenosum and tumor necrosis factor alpha agents. Cutis. 2013;92(4):E1–E2.
   PubMedGoogle Scholar
• Vandevyvere K, Luyten FP, Verschueren P, et al. Pyoderma gangrenosum developing during therapy with TNF-alpha antagonists in a patient with rheumatoid arthritis. Clin Rheumatol. 2007;26:2205–2206.
   PubMed Web of Science ®Google Scholar
• Guedes R, Moreira A, Menezes N, et al. Treatment of thalidomide resistant pyoderma gangrenosum with etanercept. Acta Dermatovenerol Croat. 2012;20:175–180.
   PubMed Web of Science ®Google Scholar
• Kowalzick L, Bertolini J, Baumann C, et al. Paradoxical reaction to etanercept: development of pyoderma gangraenosum during therapy of psoriasis arthritis. J Dtsch Dermatol Ges. 2013;11:447–449.
   PubMed Web of Science ®Google Scholar
• Haridas V, Shetty P, Dsouza LC, et al. Pyoderma gangrenosum in Sjögren’s syndrome and its successful treatment with topical application of etanercept. Int J Rheum Dis. 2017;20:657–659.
   PubMed Web of Science ®Google Scholar
• Sandborn WJ, Feagan BG, Stoinov S, et al. Certolizumab pegol for the treatment of Crohn’s disease. N Engl J Med. 2007;357:228–238.
   PubMed Web of Science ®Google Scholar
• UCB Inc. Cimzia (certolizumab) prescribing information. US FDA Safety Information. 2016.
   Google Scholar
• Cinotti E, Labeille B, Perrot JL, et al. Certolizumab for the treatment of refractory disseminated pyoderma gangrenosum associated with rheumatoid arthritis. Clin Exp Dermatol. 2014;39:750–751.
   PubMed Web of Science ®Google Scholar
• Hurabielle C, Schneider P, Baudry C, et al. Certolizumab pegol – a new therapeutic option for refractory disseminated pyoderma gangrenosum associated with Crohn’s disease. J Dermatolog Treat. 2016;27:67–69.
   PubMed Web of Science ®Google Scholar
• Janssen Biotech Inc. Simponi (golimumab) prescribing information. US FDA Safety Information. 2016.
   Google Scholar
• Janssen Biotech Inc. Simponi aria (golimumab) prescribing information. US FDA Safety Information. 2016.
   Google Scholar
• Goldminz AM, Botto NC, Gottlieb AB. Severely recalcitrant pyoderma gangrenosum successfully treated with ustekinumab. J Am Acad Dermatol. 2012;67:e237–e238.
   PubMed Web of Science ®Google Scholar
• Skalkou A, Manoli SM, Sachinidis A, et al. Pyoderma gangrenosum and pyogenic arthritis presenting as severe sepsis in a rheumatoid arthritis patient treated with golimumab. Rheumatol Int. 2018;38:161–167.
   PubMed Web of Science ®Google Scholar
• Braun-Falco M, Kovnerystyy O, Lohse P, et al. Pyoderma gangrenosum, acne, and suppurative hidradenitis (PASH) – a new autoinflammatory syndrome distinct from PAPA syndrome. J Am Acad Dermatol. 2012;66:409–415.
   PubMed Web of Science ®Google Scholar
• Marzano AV, Trevisan V, Gattorno M, et al. Pyogenic arthritis, pyoderma gangrenosum, acne, and hidradenitis suppurativa (PAPASH): a new autoinflammatory syndrome associated with a novel mutation of the PSTPIP1 gene. JAMA Dermatol. 2013;149:762–764.
   PubMed Web of Science ®Google Scholar
• Smith EJ, Allantaz F, Bennett L, et al. Clinical, molecular, and genetic characteristics of PAPA syndrome: a review. Curr Genomics. 2010;11:519–527.
   PubMed Web of Science ®Google Scholar
• Shoham NG, Centola M, Mansfield E, et al. Pyrin binds the PSTPIP1/CD2BP1 protein, defining familial Mediterranean fever and PAPA syndrome as disorders in the same pathway. Proc Natl Acad Sci USA. 2003;100:13501–13506.
   PubMed Web of Science ®Google Scholar
• Fleischmann R, Stern R, Iqbal I. Anakinra: an inhibitor of IL-1 for the treatment of rheumatoid arthritis. Expert Opin Biol Ther. 2004;4:1333–1344.
   PubMed Web of Science ®Google Scholar
• Swedish Orphan Biovitrum AB. Kineret (anakinra) prescribing information. US FDA Safety Information. 2016.
   Google Scholar
• Economides AN, Carpenter LR, Rudge JS, et al. Cytokine traps: multi-component, high-affinity blockers of cytokine action. Nat Med. 2003;9:47–52.
   PubMed Web of Science ®Google Scholar
• Brenner M, Ruzicka T, Plewig G, et al. Targeted treatment of pyoderma gangrenosum in PAPA (pyogenic arthritis, pyoderma gangrenosum and acne) syndrome with the recombinant human interleukin-1 receptor antagonist anakinra. Br J Dermatol. 2009;161:1199–1201.
   PubMed Web of Science ®Google Scholar
• Hsiao JL, Antaya RJ, Berger T, et al. Hidradenitis suppurativa and concomitant pyoderma gangrenosum: a case series and literature review. Arch Dermatol. 2010;146:1265–1270.
   PubMedGoogle Scholar
• Acquitter M, Plantin P, Kupfer I, et al. Anakinra improves pyoderma gangrenosum in psoriatic arthritis: a case report. Ann Intern Med. 2015;163:70–71.
   PubMed Web of Science ®Google Scholar
• Zeeli T, Padalon-Brauch G, Ellenbogen E, et al. Pyoderma gangrenosum, acne and ulcerative colitis in a patient with a novel mutation in the PSTPIP1 gene. Clin Exp Dermatol. 2015;40:367–372.
   PubMed Web of Science ®Google Scholar
• Beynon C, Chin MF, Hunasehally P, et al. Successful treatment of autoimmune disease-associated pyoderma gangrenosum with the IL-1 receptor antagonist anakinra: a case series of 3 patients. J Clin Rheumatol. 2017;23:181–183.
   PubMed Web of Science ®Google Scholar
• Jennings L, Molloy O, Quinlan C, et al. Treatment of pyoderma gangrenosum, acne, suppurative hidradenitis (PASH) with weight-based anakinra dosing in a Hepatitis B carrier. Int J Dermatol. 2017;56:e128–e129.
   PubMed Web of Science ®Google Scholar
• Mercuri SR, Paolino G, De Flammineis E, et al. Successful treatment of pyoderma gangrenosum with anakinra in a patient with Wiskott-Aldrich syndrome. Dermatol Ther. 2018;31:e12582.
   PubMed Web of Science ®Google Scholar
• Dhimolea E. Canakinumab. MAbs. 2010;2:3–13.
   PubMed Web of Science ®Google Scholar
• Novartis Pharmaceuticals Corporation. Ilaris (canakinumab) prescribing information. US FDA Safety Information. 2016.
   Google Scholar
• Kolios AG, Maul JT, Meier B, et al. Canakinumab in adults with steroid-refractory pyoderma gangrenosum. Br J Dermatol. 2015;173:1216–1223.
   PubMed Web of Science ®Google Scholar
• Geusau A, Mothes-Luksch N, Nahavandi H, et al. Identification of a homozygous PSTPIP1 mutation in a patient with a PAPA-like syndrome responding to canakinumab treatment. JAMA Dermatol. 2013;149:209–215.
   PubMed Web of Science ®Google Scholar
• Jaeger T, Andres C, Grosber M, et al. Pyoderma gangrenosum and concomitant hidradenitis suppurativa – rapid response to canakinumab (anti-IL-1beta). Eur J Dermatol. 2013;23:408–410.
   PubMed Web of Science ®Google Scholar
• Sun NZ, Ro T, Jolly P, et al. Non-response to interleukin-1 antagonist canakinumab in two patients with refractory pyoderma gangrenosum and hidradenitis suppurativa. J Clin Aesthet Dermatol. 2017;10:36–38.
   PubMedGoogle Scholar
• Huang W, Nath R, Zayed H, et al. Results of an open-label, proof of concept study of gevokizumab in the treatment of the acute, inflammatory phase of pyoderma gangrenosum. 2014.
   Google Scholar
• XOMA Corporation. XOMA initiates pivotal phase 3 gevokizumab study in patients with pyoderma gangrenosum. 2014.
   Google Scholar
• Keown A. Embattled bay area XOMA terminates gevokizumab trials. Biospace.com. 2016.
   Google Scholar
• Janssen Biotech Inc. Stelara (ustekinumab) prescribing information. US FDA Safety Information. 2016.
   Google Scholar
• Yeilding N, Szapary P, Brodmerkel C, et al. Development of the IL-12/23 antagonist ustekinumab in psoriasis: past, present, and future perspectives – an update. Ann NY Acad Sci. 2012;1263:1–12.
   PubMed Web of Science ®Google Scholar
• Benson JM, Peritt D, Scallon BJ, et al. Discovery and mechanism of ustekinumab: a human monoclonal antibody targeting interleukin-12 and interleukin-23 for treatment of immune-mediated disorders. MAbs. 2011;3:535–545.
   PubMed Web of Science ®Google Scholar
• Tang C, Chen S, Qian H, et al. Interleukin-23: as a drug target for autoimmune inflammatory diseases. Immunology. 2012;135:112–124.
   PubMed Web of Science ®Google Scholar
• Ye P, Rodriguez FH, Kanaly S, et al. Requirement of interleukin 17 receptor signaling for lung CXC chemokine and granulocyte colony-stimulating factor expression, neutrophil recruitment, and host defense. J Exp Med. 2001;194:519–527.
   PubMed Web of Science ®Google Scholar
• Fahmy M, Ramamoorthy S, Hata T, et al. Ustekinumab for peristomal pyoderma gangrenosum. Am J Gastroenterol. 2012;107:794–795.
   PubMed Web of Science ®Google Scholar
• Greb JE, Gottlieb AB, Goldminz AM. High-dose ustekinumab for the treatment of severe, recalcitrant pyoderma gangrenosum. Dermatol Ther. 2016;29:482–483.
   PubMed Web of Science ®Google Scholar
• Benzaquen M, Monnier J, Beaussault Y, et al. Pyoderma gangrenosum arising during treatment of psoriasis with adalimumab: effectiveness of ustekinumab. Australas J Dermatol. 2017;58:e270–e271.
   PubMed Web of Science ®Google Scholar
• Cosgarea I, Lovric Z, Korber A, et al. Successful treatment of refractory pyoderma gangrenosum with ustekinumab only after excision of renal cell carcinoma. Int Wound J. 2016;13:1041–1042.
   PubMed Web of Science ®Google Scholar
• Low ZM, Mar A. Treatment of severe recalcitrant pyoderma gangrenosum with ustekinumab. Australas J Dermatol. 2018;59(2):131–134.
   PubMed Web of Science ®Google Scholar
• Papp K, Thaci D, Reich K, et al. Tildrakizumab (MK-3222), an anti-interleukin-23p19 monoclonal antibody, improves psoriasis in a phase IIb randomized placebo-controlled trial. Br J Dermatol. 2015;173:930–939.
   PubMed Web of Science ®Google Scholar
• Zhuang Y, Calderon C, Marciniak SJ Jr, et al. First-in-human study to assess guselkumab (anti-IL-23 mAb) pharmacokinetics/safety in healthy subjects and patients with moderate-to-severe psoriasis. Eur J Clin Pharmacol. 2016;72:1303–1310.
   PubMed Web of Science ®Google Scholar
• Lee WS, Choi YJ, Yoo WH. Use of tocilizumab in a patient with pyoderma gangrenosum and rheumatoid arthritis. J Eur Acad Dermatol Venereol. 2017;31:e75–e77.
   PubMed Web of Science ®Google Scholar
• Genentech Inc. Actemra (tocilizumab) prescribing information. US FDA Safety Information. 2016.
   Google Scholar
• Cole MS, Stellrecht KE, Shi JD, et al. HuM291, a humanized anti-CD3 antibody, is immunosuppressive to T cells while exhibiting reduced mitogenicity in vitro. Transplantation. 1999;68:563–571.
   PubMed Web of Science ®Google Scholar
• Yu QT, Saruta M, Papadakis KA. Visilizumab induces apoptosis of mucosal T lymphocytes in ulcerative colitis through activation of caspase 3 and 8 dependent pathways. Clin Immunol. 2008;127:322–329.
   PubMed Web of Science ®Google Scholar
• Chau LA, Tso JY, Melrose J, et al. HuM291(Nuvion), a humanized Fc receptor-nonbinding antibody against CD3, anergizes peripheral blood T cells as partial agonist of the T cell receptor. Transplantation. 2001;71:941–950.
   PubMed Web of Science ®Google Scholar
• Lőrincz M, Kleszky M, Szalóki T Jr, et al. Pyoderma gangrenosum treated successfully with visilizumab in patients with ulcerative colitis. Orv Hetil. 2010;151:144–147.
   PubMedGoogle Scholar
• Sandborn WJ, Colombel JF, Frankel M, et al. Anti-CD3 antibody visilizumab is not effective in patients with intravenous corticosteroid-refractory ulcerative colitis. Gut. 2010;59:1485–1492.
   PubMed Web of Science ®Google Scholar
• Takeda Pharmaceutical Company. ENTYVIO (vedolizumab) prescribing information. 2018.
   Google Scholar
• Wyant T, Fedyk E, Abhyankar B. An overview of the mechanism of action of the monoclonal antibody vedolizumab. J Crohns Colitis. 2016;10:1437–1444.
   PubMed Web of Science ®Google Scholar
• Fleisher M, Marsal J, Lee SD, et al. Effects of vedolizumab therapy on extraintestinal manifestations in inflammatory bowel disease. Dig Dis Sci. 2018;63:825–833.
   PubMed Web of Science ®Google Scholar
• O’Shea JJ, Murray PJ. Cytokine signaling modules in inflammatory responses. Immunity. 2008;28:477–487.
   PubMed Web of Science ®Google Scholar
• Wohlmann A, Sebastian K, Borowski A, et al. Signal transduction by the atopy-associated human thymic stromal lymphopoietin (TSLP) receptor depends on Janus kinase function. Biol Chem. 2010;391:181–186.
   PubMed Web of Science ®Google Scholar
• Incyte Corporation. Jakafi (ruxolitinib) prescribing information. US FDA Safety Information. 2016.
   Google Scholar
• Pfizer Inc. XELJANZ (tofacitinib) prescribing information. US FDA Safety Information. 2016.
   Google Scholar
• Shanmugam VK, McNish S, Shara N, et al. Chronic leg ulceration associated with polycythemia vera responding to ruxolitinib (Jakafi(®)). J Foot Ankle Surg. 2013;52:781–785.
   PubMed Web of Science ®Google Scholar
• Nasifoglu S, Heinrich B, Welzel J. Successful therapy of pyoderma gangrenosum with a JAK2 inhibitor. Br J Dermatol. 2018. [Epub ahead of print].
   PubMed Web of Science ®Google Scholar
• Manning CD, Burman M, Christensen SB, et al. Suppression of human inflammatory cell function by subtype-selective PDE4 inhibitors correlates with inhibition of PDE4A and PDE4B. Br J Pharmacol. 1999;128:1393–1398.
   PubMed Web of Science ®Google Scholar
• Celgene Corporation. OTEZLA (apremilast) prescribing information. Celgenecom. 2017.
   Google Scholar
• Schafer PH, Parton A, Gandhi AK, et al. Apremilast, a cAMP phosphodiesterase-4 inhibitor, demonstrates anti-inflammatory activity in vitro and in a model of psoriasis. Br J Pharmacol. 2010;159:842–855.
   PubMed Web of Science ®Google Scholar
• Laird ME, Tong LX, Lo Sicco KI, et al. Novel use of apremilast for adjunctive treatment of recalcitrant pyoderma gangrenosum. JAAD Case Rep. 2017;3:228–229.
   PubMedGoogle Scholar
• Maibach HI, Gorouhi F. Evidence based dermatology. Shelton (USA): PMPH; 2011.
   Google Scholar
• Kaufman I, Caspi D, Yeshurun D, et al. The effect of infliximab on extraintestinal manifestations of Crohn’s disease. Rheumatol Int. 2005;25:406–410.
   PubMed Web of Science ®Google Scholar
• Kiran RP, O’Brien-Ermlich B, Achkar JP, et al. Management of peristomal pyoderma gangrenosum. Dis Colon Rectum. 2005;48:1397–1403.
   PubMed Web of Science ®Google Scholar
• Marzano AV, Trevisan V, Lazzari R, et al. Pyoderma gangrenosum: study of 21 patients and proposal of a ‘clinicotherapeutic’ classification. J Dermatolog Treat. 2011;22:254–260.
   PubMed Web of Science ®Google Scholar
• Adışen E, Öztaş M, Gürer MA. Treatment of idiopathic pyoderma gangrenosum with infliximab: induction dosing regimen or on-demand therapy? Dermatology. 2008;216:163–165.
   PubMed Web of Science ®Google Scholar
• Akhras V, Sarkany R, Walsh S, et al. Superficial granulomatous pyoderma treated preoperatively with infliximab. Clin Exp Dermatol. 2009;34:e183–e185.
   PubMed Web of Science ®Google Scholar
• Andrisani G, Guidi L, Papa A, et al. A case of pyoderma gangrenosum with ulcerative colitis treated with combined approach: infliximab and surgery. J Crohns Colitis. 2013;7:421–426.
   PubMed Web of Science ®Google Scholar
• Arnott ID, McDonald D, Williams A, et al. Clinical use of Infliximab in Crohn’s disease: the Edinburgh experience. Aliment Pharmacol Ther. 2001;15:1639–1646.
   PubMed Web of Science ®Google Scholar
• Baglieri F, Scuderi G. Therapeutic hotline. Infliximab for treatment of resistant pyoderma gangrenosum associated with ulcerative colitis and psoriasis. A case report. Dermatol Ther. 2010;23:541–543.
   PubMed Web of Science ®Google Scholar
• Baliu PC, Mascaro JM Jr. Multifocal and refractory pyoderma gangrenosum: possible role of cocaine abuse. Australas J Dermatol. 2017;58:e83–e86.
   PubMed Web of Science ®Google Scholar
• Batres LA, Mamula P, Baldassano RN. Resolution of severe peristomal pyoderma gangrenosum with infliximab in a child with Crohn disease. J Pediatr Gastroenterol Nutr. 2002;34:558–560.
   PubMed Web of Science ®Google Scholar
• Bhatti H, Khalid N, Rao B. Superficial pyoderma gangrenosum treated with infliximab: a case report. Cutis. 2012;90:297–299.
   PubMed Web of Science ®Google Scholar
• Bobbitt SA, Klaus EM, Stringer E, et al. Treatment of refractory pyoderma gangrenosum with infliximab in a 17-month-old boy. Dermatol Online J. 2016;22(4):9.
   PubMedGoogle Scholar
• Botros N, Pickover L, Das KM. Image of the Month. Pyoderma gangrenosum caused by ulcerative colitis. Gastroenterology. 2000;118:654, 809.
   PubMedGoogle Scholar
• Brunasso AM, Laimer M, Massone C. Paradoxical reactions to targeted biological treatments: a way to treat and trigger? Acta Derm Venereol. 2010;90:183–185.
   PubMed Web of Science ®Google Scholar
• Byeon YM, Lee J, Lee SJ, et al. peritonsillar involvement in pyoderma gangrenosum associated with ulcerative colitis. Intest Res. 2014;12:153–156.
   PubMedGoogle Scholar
• Campos-Munoz L, Conde-Taboada A, Aleo E, et al. Refractory pyoderma gangrenosum treated with infliximab in an infant. Clin Exp Dermatol. 2014;39:336–339.
   PubMed Web of Science ®Google Scholar
• Carrasco Cubero C, Ruiz Tudela MM, Salaberri Maestrojuan JJ, et al. Pyoderma gangrenosum associated with inflammatory bowel disease. Report of two cases with good response to infliximab. Reumatol Clin. 2012;8:90–92.
   PubMedGoogle Scholar
• Castro FM, Sanchez MD, Ruiz-Granados E, et al. Coexistence of pyoderma gangrenosum and Sweet’s syndrome in a patient with ulcerative colitis. Am J Gastroenterol. 2007;102:2865–2866.
   PubMed Web of Science ®Google Scholar
• Chan JL, Graves MS, Cockerell CJ, et al. Rapid improvement of pyoderma gangrenosum after treatment with infliximab. J Drugs Dermatol. 2010;9:702–704.
   PubMed Web of Science ®Google Scholar
• Chatzinasiou F, Polymeros D, Panagiotou M, et al. Generalized pyoderma gangrenosum associated with ulcerative colitis: successful treatment with infliximab and azathioprine. Acta Dermatovenerol Croat. 2016;1: 83–85.
   Google Scholar
• Cocco A, Angelucci E, Viscido A, et al. Successful treatment with infliximab of refractory pyoderma gangrenosum in 2 patients with inflammatory bowel diseases. Inflamm Bowel Dis. 2007;13:1317–1319.
   PubMed Web of Science ®Google Scholar
• Crouse L, McShane D, Morrell DS, et al. Pyoderma gangrenosum in an infant: a case report and review of the literature. Pediatr Dermatol. 2018 [Epub ahead of print].
   PubMed Web of Science ®Google Scholar
• Culver EL, Salmon JF, Frith P, et al. Recurrent posterior scleritis and orbital myositis as extra-intestinal manifestations of Crohn’s disease: case report and systematic literature review. J Crohns Colitis. 2008;2:337–342.
   PubMed Web of Science ®Google Scholar
• De la Morena F, Martin L, Gisbert JP, et al. Refractory and infected pyoderma gangrenosum in a patient with ulcerative colitis: response to infliximab. Inflamm Bowel Dis. 2007;13:509–510.
   PubMed Web of Science ®Google Scholar
• Dini V, Romanelli M, Bertone M, et al. Improvement of idiopathic pyoderma gangrenosum during treatment with anti-tumor necrosis factor alfa monoclonal antibody. Int J Low Extrem Wounds. 2007;6:108–113.
   PubMedGoogle Scholar
• Duchini G, Itin P, Arnold A. A case of refractory pyoderma gangrenosum treated with a combination of Apligraf and systemic immunosuppressive agents. Adv Skin Wound Care. 2011;24:217–220.
   PubMed Web of Science ®Google Scholar
• Eaton PA, Callen JP. Mycophenolate mofetil as therapy for pyoderma gangrenosum. Arch Dermatol. 2009;145:781–785.
   PubMed Web of Science ®Google Scholar
• Ermis F, Ozdil S, Akyuz F, et al. Pyoderma gangrenosum treated with infliximab in inactive ulcerative colitis. Inflamm Bowel Dis. 2008;14:1611–1613.
   PubMed Web of Science ®Google Scholar
• Ferkolj I, Hocevar A, Golouh R, et al. Infliximab for treatment of resistant pyoderma gangrenosum associated with Crohn’s disease. Acta Dermatovenerol Alp Pannonica Adriat. 2006;15:173–177.
   PubMedGoogle Scholar
• Fernandez A, Velasco A, Prieto V, et al. Response to infliximab in atypical pyoderma gangrenosum associated with ulcerative colitis. Am J Gastroenterol. 2008;103:2951–2952.
   PubMed Web of Science ®Google Scholar
• Freedberg DE, Husain S, Swaminath A. Education and imaging. Gastrointestinal: severe inflammatory bowel disease-associated pyoderma gangrenosum. J Gastroenterol Hepatol. 2013;28:1691.
   PubMed Web of Science ®Google Scholar
• Gade M, Studstrup F, Andersen AK, et al. Pulmonary manifestations of pyoderma gangrenosum: 2 cases and a review of the literature. Respir Med. 2015;109:443–450.
   PubMed Web of Science ®Google Scholar
• Ghosn S, Malek J, Shbaklo Z, et al. Takayasu disease presenting as malignant pyoderma gangrenosum in a child with relapsing polychondritis. J Am Acad Dermatol. 2008;59:S84–S87.
   PubMed Web of Science ®Google Scholar
• Goldshmid O, Dovorish Z, Zehavi T, et al. Coexistent pyoderma gangrenosum and tibialis anterior myositis as presenting manifestations of Crohn’s disease: case report and review of the literature. Rheumatol Int. 2011;31:525–527.
   PubMed Web of Science ®Google Scholar
• Grange F, Djilali-Bouzina F, Weiss AM, et al. Corticosteroid-resistant pyoderma gangrenosum associated with Crohn’s disease: rapid cure with infliximab. Dermatology. 2002;205:278–280.
   PubMed Web of Science ®Google Scholar
• Groleau PF, Grossberg AL, Gaspari AA. Hidradenitis suppurativa and concomitant pyoderma gangrenosum treated with infliximab. Cutis. 2015;95:337–342.
   PubMed Web of Science ®Google Scholar
• Hayashi H, Kuwabara C, Tarumi K, et al. Successful treatment with infliximab for refractory pyoderma gangrenosum associated with inflammatory bowel disease. J Dermatol. 2012;39:576–578.
   PubMed Web of Science ®Google Scholar
• Hewitt D, Tait C. Use of infliximab in pyoderma gangrenosum. Australas J Dermatol. 2007;48:95–98.
   PubMed Web of Science ®Google Scholar
• Hong JJ, Merel NH, Hanauer SB. Treatment of pyoderma gangrenosum (PG) complicating Crohn’s disease (CD) with infliximab. Gastroenterology. 2001;120:A621.
   Web of Science ®Google Scholar
• Hughes AP, Jackson JM, Callen JP. Clinical features and treatment of peristomal pyoderma gangrenosum. JAMA. 2000;284:1546–1548.
   PubMed Web of Science ®Google Scholar
• Ito T, Sato N, Yamazaki H, et al. A case of aseptic abscesses syndrome treated with corticosteroids and TNF-alpha blockade. Mod Rheumatol. 2013;23:195–199.
   PubMed Web of Science ®Google Scholar
• Jaimes-Lopez N, Molina V, Arroyave JE, et al. Development of pyoderma gangrenosum during therapy with infliximab. J Dermatol Case Rep. 2009;3:20–23.
   PubMedGoogle Scholar
• Jenne L, Sauter B, Thumann P, et al. Successful treatment of therapy-resistant chronic vegetating pyoderma gangrenosum with infliximab (chimeric antitumour necrosis factor antibody). Br J Dermatol. 2004;150:380–382.
   PubMed Web of Science ®Google Scholar
• Juillerat P, Christen-Zach S, Troillet FX, et al. Infliximab for the treatment of disseminated pyoderma gangrenosum associated with ulcerative colitis. Case report and literature review. Dermatology. 2007;215:245–251.
   PubMed Web of Science ®Google Scholar
• Kaur MR, Lewis HM. Severe recalcitrant pyoderma gangrenosum treated with infliximab. Br J Dermatol. 2005;153:689–691.
   PubMed Web of Science ®Google Scholar
• Kouklakis G, Moschos J, Leontiadis GI, et al. Infliximab for treatment of pyoderma gangrenosum associated with clinically inactive Crohn’s disease. A case report. Rom J Gastroenterol. 2005;14:401–403.
   PubMedGoogle Scholar
• Kugathasan S, Miranda A, Nocton J, et al. Dermatologic manifestations of Crohn disease in children: response to infliximab. J Pediatr Gastroenterol Nutr. 2003;37:150–154.
   PubMed Web of Science ®Google Scholar
• Ljung T, Staun M, Grove O, et al. Pyoderma gangrenosum associated with Crohn disease: effect of TNF-alpha blockade with infliximab. Scand J Gastroenterol. 2002;37:1108–1110.
   PubMed Web of Science ®Google Scholar
• Lopez San Roman A, Bermejo F, Aldanondo I, et al. Pyoderma gangrenosum associated with ulcerative colitis: response to infliximab. Rev Esp Enferm Dig. 2004;96:420–422. 422-4.
   PubMed Web of Science ®Google Scholar
• Marzano AV, Tourlaki A, Alessi E, et al. Widespread idiopathic pyoderma gangrenosum evolved from ulcerative to vegetative type: a 10-year history with a recent response to infliximab. Clin Exp Dermatol. 2008;33:156–159.
   PubMed Web of Science ®Google Scholar
• Meng X, Zhu X, Chen L, et al. Pyoderma gangrenosum of articulations carpi associated with ulcerative colitis: one case report. Int J Clin Exp Med. 2015;8:19184–19187.
   PubMed Web of Science ®Google Scholar
• Mimouni D, Anhalt GJ, Kouba DJ, et al. Infliximab for peristomal pyoderma gangrenosum. Br J Dermatol. 2003;148:813–816.
   PubMed Web of Science ®Google Scholar
• Mittal S, Graham V. Skin lesions mimicking septic arthritis. J Fam Pract. 2006;55:881–884.
   PubMed Web of Science ®Google Scholar
• Molnar T, Farkas K, Nagy F, et al. Successful use of infliximab for treating fistulizing pouchitis with severe extraintestinal manifestation: a case report. Inflamm Bowel Dis. 2008;14:1752–1753.
   PubMed Web of Science ®Google Scholar
• Mooij JE, van Rappard DC, Mekkes JR. Six patients with pyoderma gangrenosum successfully treated with infliximab. Int J Dermatol. 2013;52:1418–1420.
   PubMedGoogle Scholar
• Moschella SL. Is there a role for infliximab in the current therapy of hidradenitis suppurativa? A report of three treated cases. Int J Dermatol. 2007;46:1287–1291.
   PubMed Web of Science ®Google Scholar
• Neesse A, Michl P, Kunsch S, et al. Simultaneous onset of ulcerative colitis and disseminated pyoderma gangrenosum. Case Rep Gastroenterol. 2007;1:110–115.
   PubMedGoogle Scholar
• Nord KM, Pappert AS, Grossman ME. Pyoderma gangrenosum-like lesions in leukocyte adhesion deficiency I treated with intravenous immunoglobulin. Pediatr Dermatol. 2011;28:156–161.
   PubMed Web of Science ®Google Scholar
• Patier de la Pena JL, Moreno-Cobo MA, Sanchez-Conde M, et al. Behçet disease and refractory pyoderma gangrenosum with response to infliximab. Rev Clin Esp. 2015;215:66–67.
   PubMed Web of Science ®Google Scholar
• Poritz LS, Lebo MA, Bobb AD, et al. Management of peristomal pyoderma gangrenosum. J Am Coll Surg. 2008;206:311–315.
   PubMed Web of Science ®Google Scholar
• Rajan N, Das S, Taylor A, et al. Idiopathic infantile pyoderma gangrenosum with stridor responsive to infliximab. Pediatr Dermatol. 2009;26:65–69.
   PubMed Web of Science ®Google Scholar
• Regueiro M, Valentine J, Plevy S, et al. Infliximab for treatment of pyoderma gangrenosum associated with inflammatory bowel disease. Am J Gastroenterol. 2003;98:1821–1826.
   PubMed Web of Science ®Google Scholar
• Rispo A, Scarpa R, Di Girolamo E, et al. Infliximab in the treatment of extra-intestinal manifestations of Crohn’s disease. Scand J Rheumatol. 2005;34:387–391.
   PubMed Web of Science ®Google Scholar
• Romero GM, Sanchez MD. Infliximab induces remission of pyoderma gangrenosum. Eur J Gastroenterol Hepatol. 2002;14:907.
   PubMed Web of Science ®Google Scholar
• Rumeileh IA, Furlan C, Minatel E, et al. Radiation therapy for recalcitrant pyoderma gangrenosum. G Ital Dermatol Venereol. 2014;149:145–148.
   PubMed Web of Science ®Google Scholar
• Sapienza MS, Cohen S, Dimarino AJ. Treatment of pyoderma gangrenosum with infliximab in Crohn’s disease. Dig Dis Sci. 2004;49:1454–1457.
   PubMed Web of Science ®Google Scholar
• Shareef MS, Munro LR, Owen RG, et al. Progression of IgA gammopathy to myeloma following infliximab treatment for pyoderma gangrenosum. Clin Exp Dermatol. 2012;37:146–148.
   PubMed Web of Science ®Google Scholar
• Sheldon DG, Sawchuk LL, Kozarek RA, et al. Twenty cases of peristomal pyoderma gangrenosum: diagnostic implications and management. Arch Surg. 2000;135:564–568. discussion 568-9.
   PubMed Web of Science ®Google Scholar
• Sinagra E, Orlando A, Renna S, et al. Multifocal pyoderma gangrenosum resistant to infliximab in active ulcerative colitis: don’t forget the role of cyclosporin. Inflamm Bowel Dis. 2012;18:E1594–E1595.
   PubMed Web of Science ®Google Scholar
• Singh M, Andrew SM, Lear JT. Infliximab as a treatment for recalcitrant pyoderma gangrenosum. Clin Exp Dermatol. 2004;29:196–197.
   PubMed Web of Science ®Google Scholar
• Stichweh DS, Punaro M, Pascual V. Dramatic improvement of pyoderma gangrenosum with infliximab in a patient with PAPA syndrome. Pediatr Dermatol. 2005;22:262–265.
   PubMed Web of Science ®Google Scholar
• Stiegler JD, Lucas CT, Sami N. Pyoderma gangrenosum in pregnancy successfully treated with infliximab and prednisone. JAAD Case Rep. 2017;3:387–389.
   PubMedGoogle Scholar
• Swale VJ, Saha M, Kapur N, et al. Pyoderma gangrenosum outside the context of inflammatory bowel disease treated successfully with infliximab. Clin Exp Dermatol. 2005;30:134–136.
   PubMed Web of Science ®Google Scholar
• Tada M, Nakanishi T, Hirata C, et al. Use of infliximab in a patient with pyoderma gangrenosum and rheumatoid arthritis. Mod Rheumatol. 2010;20:598–601.
   PubMedGoogle Scholar
• Tai YJ, Kelly R. Pyoderma gangrenosum complicated by herpes simplex virus infection. Australas J Dermatol. 2005;46:161–164.
   PubMedGoogle Scholar
• Tan MH, Gordon M, Lebwohl O, et al. Improvement of pyoderma gangrenosum and psoriasis associated with Crohn disease with anti-tumor necrosis factor alpha monoclonal antibody. Arch Dermatol. 2001;137:930–933.
   PubMed Web of Science ®Google Scholar
• Teich N. Failure of sublesional infliximab injection for refractory parastomal pyoderma gangrenosum in a patient with Crohn’s disease. Tech Coloproctol. 2014;18:965–966.
   PubMed Web of Science ®Google Scholar
• Teich N, Klugmann T. Rapid improvement of refractory pyoderma gangrenosum with infliximab gel in a patient with ulcerative colitis. J Crohns Colitis. 2014;8:85–86.
   PubMed Web of Science ®Google Scholar
• Tolkachjov SN, Fahy AS, Wetter DA, et al. Postoperative pyoderma gangrenosum (PG): the Mayo Clinic experience of 20 years from 1994 through 2014. J Am Acad Dermatol. 2015;73:615–622.
   PubMed Web of Science ®Google Scholar
• Triantafillidis JK, Cheracakis P, Sklavaina M, et al. Favorable response to infliximab treatment in a patient with active Crohn disease and pyoderma gangrenosum. Scand J Gastroenterol. 2002;37:863–865.
   PubMed Web of Science ®Google Scholar
• Ueda M, Katoh M, Tanizaki H, et al. Refractory pyoderma gangrenosum associated with ulcerative colitis successfully treated with infliximab. Dermatol Online J. 2016;1:12.
   Google Scholar
• Uthman I, Kanj N, El-Sayad J, et al. Miliary tuberculosis after infliximab therapy in Lebanon. Clin Rheumatol. 2004;23:279–280.
   PubMed Web of Science ®Google Scholar
• Uthman I, El-Sayad J, Sharara A. Successful treatment of recalcitrant pyoderma gangrenosum with infliximab complicated by tuberculosis despite negative screening tests. Clin Exp Dermatol. 2005;30:294.
   PubMed Web of Science ®Google Scholar
• Vestita M, Guida S, Mazzoccoli S, et al. Late paradoxical development of pyoderma gangrenosum in a psoriasis patient treated with infliximab. Eur J Dermatol. 2015;25:272–273.
   PubMed Web of Science ®Google Scholar
• Williamson KD, Nguyen NQ. A large shin ulcer after minor trauma: please do not debride! Gastroenterology. 2012;143:e11–e12.
   PubMed Web of Science ®Google Scholar
• Wolbing F, Fierlbeck G, Hotzenecker W, et al. Septic shock after treatment of pyoderma gangrenosum with infliximab. Acta Derm Venereol. 2009;89:93–94.
   PubMed Web of Science ®Google Scholar
• Zaccagna A, Bertone A, Puiatti P, et al. Anti-tumor necrosis factor alpha monoclonal antibody (infliximab) for the treatment of pyoderma gangrenosum associated with Crohn’s disease. Eur J Dermatol. 2003;13:258–260.
   PubMed Web of Science ®Google Scholar
• Zampeli VA, Lippert U, Nikolakis G, et al. Disseminated refractory pyoderma gangraenosum during an ulcerative colitis flare. Treatment with infliximab. J Dermatol Case Rep. 2015;9:62–66.
   PubMed Web of Science ®Google Scholar
• Schwartzfarb EM, Weir D, Conlan WA, et al. Pyoderma gangrenosum in a patient with Bruton’s X-linked agammaglobulinemia: shared pathogenesis of altered tumor necrosis factor alpha? J Clin Aesthet Dermatol. 2008;1:26–29.
   PubMedGoogle Scholar
• Donmez S, Pamuk ON, Gedik M, et al. A case of granulomatosis with polyangiitis and pyoderma gangrenosum successfully treated with infliximab and rituximab. Int J Rheum Dis. 2014;17:471–475.
   PubMed Web of Science ®Google Scholar
• Del Giacco SR, Firinu D, Lorrai MM, et al. Idiopathic pyoderma gangrenosum: successful resolution with infliximab therapy and pro-inflammatory cytokines assessment. Acta Derm Venereol. 2012;92:439–440.
   PubMed Web of Science ®Google Scholar
• Kokavec J, Rajak S, Huilgol S, et al. Pyoderma gangrenosum of the eyelid. Can J Ophthalmol. 2016;51:e58–e60.
   PubMed Web of Science ®Google Scholar